RA associates with an increased burden of cardiovascular disease, which is at least partially
attributed to classical risk factors such as hypertension (HT) and dyslipidaemia. HT is highly …

Objective To develop recommendations on monitoring for adverse events (AEs) of low-dose
glucocorticoid (GC) therapy (≤ 7.5 mg prednisone or equivalent daily) in clinical trials and …

Objective Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE)
risk. The impact of statins in RA is not established. We assessed whether atorvastatin is …

Objective. To evaluate the impact of comorbidities on achieving remission by examining
changes in the clinical disease activity index (CDAI) in RA patients in the community-based …

Background Cardiovascular disease (CVD) is partially attributed to traditional cardiovascular
risk factors, which can be identified and managed based on risk stratification algorithms …

Objective Patients with rheumatoid arthritis (RA) in whom remission is achieved following
combination therapy with methotrexate plus etanercept face an ongoing medication burden …

Objective. When treating RA patients, remission (REM) or at least low disease activity (LDA)
is the ultimate therapeutic goal. The aim of this study was to assess the impact of …

Cardiovascular disease (CVD) comorbidity is a significant issue for the inflammatory
arthritides (IA). There is a wealth of mortality studies showing increased cardiovascular …

Background Rheumatoid arthritis (RA) patients are at risk of acquiring drug-related problems
(DRPs). However, there has been a lack of studies on DRPs in patients with RA up to now …

Elderly rheumatoid arthritis (RA) is classified into two clinical subsets, elderly-onset RA
(EORA) and younger-onset elderly RA. With the improvement of life expectancy in the …